PD-L1 expression in advanced NSCLC : Insights into risk stratification and treatment selection from a systematic literature review
Copyright © 2017 AstraZeneca LP. Published by Elsevier B.V. All rights reserved..
Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway. Antibodies that block this pathway offer a promising new approach to treatment in advanced/metastatic non-small cell lung cancer (NSCLC). A systematic review of the literature was conducted to assess the association of PD-L1 with important patient and disease characteristics, the prognostic significance of PD-L1 expressing NSCLC tumors, and the value of PD-L1 as a predictive biomarker of response to anti-PD-1/PD-L1 treatments in advanced/metastatic NSCLC. A total of 35 eligible studies were selected for analysis. Methods used to determine PD-L1 in NSCLC tissue varied considerably; with different PD-L1 antibodies, antibody detection methods, and staining cut-offs. Immunohistochemistry was the most frequent type of PD-L1 assay. Overall, study evidence did not support an association between PD-L1 expression and gender, age, smoking history, tumor histology (adenocarcinoma vs. squamous cell carcinoma), performance status, pathologic tumor grade or EGFR/KRAS/ALK mutational status. In several studies, high PD-L1 expression was associated with shorter survival compared with low expression. Most evidence indicated that patients with high vs. low PD-L1 expression were more likely to experience treatment benefit with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab) in advanced NSCLC. Variability in the methods used to determine PD-L1 expression in NSCLC tissue suggests a need for standardized use of well-validated PD-L1 diagnostic assays. Although considerable research links PD-L1 expression in tumors to shorter survival in advanced/metastatic NSCLC, its use as a prognostic factor requires more study. As studies of anti-PD-1/PD-L1 agents continue, PD-L1 is likely to play an important role as a predictive biomarker for selecting patients deriving most benefit from anti-PD-1/PD-L1 monotherapy and directing patients with lower levels of tumor PD-L1 expression (with a high unmet medical need), to alternative treatments, such as combination immunotherapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Lung cancer (Amsterdam, Netherlands) - 112(2017) vom: 26. Okt., Seite 200-215 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brody, Robert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced NSCLC |
|---|
| Anmerkungen: |
Date Completed 05.07.2018 Date Revised 11.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lungcan.2017.08.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278571484 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278571484 | ||
| 003 | DE-627 | ||
| 005 | 20231225020914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2017.08.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0928.xml |
| 035 | |a (DE-627)NLM278571484 | ||
| 035 | |a (NLM)29191596 | ||
| 035 | |a (PII)S0169-5002(17)30444-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brody, Robert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PD-L1 expression in advanced NSCLC |b Insights into risk stratification and treatment selection from a systematic literature review |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2018 | ||
| 500 | |a Date Revised 11.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 AstraZeneca LP. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway. Antibodies that block this pathway offer a promising new approach to treatment in advanced/metastatic non-small cell lung cancer (NSCLC). A systematic review of the literature was conducted to assess the association of PD-L1 with important patient and disease characteristics, the prognostic significance of PD-L1 expressing NSCLC tumors, and the value of PD-L1 as a predictive biomarker of response to anti-PD-1/PD-L1 treatments in advanced/metastatic NSCLC. A total of 35 eligible studies were selected for analysis. Methods used to determine PD-L1 in NSCLC tissue varied considerably; with different PD-L1 antibodies, antibody detection methods, and staining cut-offs. Immunohistochemistry was the most frequent type of PD-L1 assay. Overall, study evidence did not support an association between PD-L1 expression and gender, age, smoking history, tumor histology (adenocarcinoma vs. squamous cell carcinoma), performance status, pathologic tumor grade or EGFR/KRAS/ALK mutational status. In several studies, high PD-L1 expression was associated with shorter survival compared with low expression. Most evidence indicated that patients with high vs. low PD-L1 expression were more likely to experience treatment benefit with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab) in advanced NSCLC. Variability in the methods used to determine PD-L1 expression in NSCLC tissue suggests a need for standardized use of well-validated PD-L1 diagnostic assays. Although considerable research links PD-L1 expression in tumors to shorter survival in advanced/metastatic NSCLC, its use as a prognostic factor requires more study. As studies of anti-PD-1/PD-L1 agents continue, PD-L1 is likely to play an important role as a predictive biomarker for selecting patients deriving most benefit from anti-PD-1/PD-L1 monotherapy and directing patients with lower levels of tumor PD-L1 expression (with a high unmet medical need), to alternative treatments, such as combination immunotherapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Advanced NSCLC | |
| 650 | 4 | |a Assay | |
| 650 | 4 | |a Checkpoint inhibitors | |
| 650 | 4 | |a Immunohistochemistry | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Prognosis | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Zhang, Yiduo |e verfasserin |4 aut | |
| 700 | 1 | |a Ballas, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Siddiqui, Mohd Kashif |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Palvi |e verfasserin |4 aut | |
| 700 | 1 | |a Barker, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Midha, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Jill |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer (Amsterdam, Netherlands) |d 1994 |g 112(2017) vom: 26. Okt., Seite 200-215 |w (DE-627)NLM074973657 |x 1872-8332 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2017 |g day:26 |g month:10 |g pages:200-215 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lungcan.2017.08.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2017 |b 26 |c 10 |h 200-215 | ||